Rocket Pharmaceuticals (9IP1) Stock Statistics & Valuation Metrics

Rocket Pharmaceuticals has a market cap or net worth of $435.87M. The enterprise value is €432.62M.

Rocket Pharmaceuticals has 108,569,145 shares outstanding. The number of shares has decreased by -2.65% in one year.

Rocket Pharmaceuticals’s return on equity (ROE) is -0.80 and return on invested capital (ROIC) is -75.38%.

The current PE Ratio of Rocket Pharmaceuticals is ―. Rocket Pharmaceuticals’s PEG ratio is 0.07.

In the last 12 months, Rocket Pharmaceuticals had revenue of 0.00 and earned -223.12M in profits. Earnings per share was -2.01.

In the last 12 months, operating cash flow was -190.03M and capital expenditures -440.00K, giving a free cash flow of -190.47M billion.

Rocket Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Rocket Pharmaceuticals upcoming earnings date is May 11, 2026, Before Open (Confirmed).

Rocket Pharmaceuticals as a current ratio of 6.38, with Debt / Equity ratio of 8.97%

In the past 12 months, Rocket Pharmaceuticals has paid 0.00 in taxes.

Rocket Pharmaceuticals EV to EBITDA ratio is -1.60, with an EV/FCF ratio of -1.77.

Rocket Pharmaceuticals has $188.93M in cash and marketable securities with $24.88M in debt, giving a net cash position of $164.05M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Rocket Pharmaceuticals is $7.86, which is 11.43% higher than the current price. The consensus rating is Moderate Buy